Compare · DRNA vs SBPH
DRNA vs SBPH
Side-by-side comparison of Dicerna Pharmaceuticals, Inc. (DRNA) and Spring Bank Pharmaceuticals, Inc. (SBPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRNA and SBPH operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- DRNA carries a market cap of $2.96B.
- DRNA has more recent analyst coverage (14 ratings vs 0 for SBPH).
- Company
- Dicerna Pharmaceuticals, Inc.
- Spring Bank Pharmaceuticals, Inc.
- Price
- $38.23+0.61%
- -
- Market cap
- $2.96B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2016
- News (4w)
- 0
- 0
- Recent ratings
- 14
- 0
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Latest DRNA
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
- SEC Form 15-12B filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form 4: Koppel Adam closing all direct ownership in the company
- SEC Form 4: Zeng Ling closing all direct ownership in the company
- SEC Form 4: Weissman James B closing all direct ownership in the company
- SEC Form 4: Smith Cynthia closing all direct ownership in the company
Latest SBPH
- CORRECTING and REPLACING Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics
- Spring Bank Pharmaceuticals Stockholders Approve Combination with F-star Therapeutics
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Investors are Encouraged to Contact the Firm – MVC, WPX, PTI, SBPH
- SHAREHOLDER ALERT: WeissLaw LLP Reminds IPHI, WPX, VRTU, and SBPH Shareholders About Its Ongoing Investigations
- Spring Bank Pharmaceuticals Announces Special Dividend of Contingent Value Rights
- Spring Bank Announces Poster Presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
- ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - MR, MYOK, CBLI, SBPH, PTI, PRCP
- SHAREHOLDER ALERT: WeissLaw LLP Reminds SBPH, CIT, CCR, and MOBL Shareholders About Its Ongoing Investigations
- ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm - AMAG, SBPH, VAR, SINA, GARS
- Spring Bank Class Action: Halper Sadeh LLP Announces Filing of Shareholder Class Action Lawsuit Against Spring Bank Pharmaceuticals, Inc.; Investors Are Encouraged to Contact the Firm - SBPH